Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
210 East Grand Avenue, South San Francisco, California
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.14K % +12.2%
Debt-to-equity 24.8 % +13.7%
Return On Equity -53.7 % -4.31%
Return On Assets -43.1 % -1.8%
Operating Margin -343K % -42.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 169M shares +15.9%
Common Stock, Shares, Outstanding 170M shares +17%
Entity Public Float 557M USD -44.8%
Common Stock, Value, Issued 170K USD +16.4%
Weighted Average Number of Shares Outstanding, Basic 169M shares +17%
Weighted Average Number of Shares Outstanding, Diluted 169M shares +17%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 87K USD -40.8%
Research and Development Expense 215M USD -22.3%
General and Administrative Expense 70.1M USD -10.5%
Operating Income (Loss) -298M USD +15.9%
Nonoperating Income (Expense) 5.85M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -292M USD +19.2%
Earnings Per Share, Basic -1.78 USD/shares +29.1%
Earnings Per Share, Diluted -1.78 USD/shares +29.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51M USD -53.6%
Cash, Cash Equivalents, and Short-term Investments 397M USD -22.7%
Assets, Current 395M USD -17.9%
Property, Plant and Equipment, Net 95.9M USD -12.7%
Operating Lease, Right-of-Use Asset 64.5M USD -21.3%
Other Assets, Noncurrent 5.16M USD -45.1%
Assets 586M USD -21.8%
Accounts Payable, Current 5.78M USD -60.7%
Employee-related Liabilities, Current 12.7M USD -29.4%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 30.9M USD -48%
Operating Lease, Liability, Noncurrent 88.9M USD -4.92%
Other Liabilities, Noncurrent 5.17M USD -0.62%
Liabilities 125M USD -21%
Accumulated Other Comprehensive Income (Loss), Net of Tax -927K USD +84.4%
Retained Earnings (Accumulated Deficit) -1.63B USD -21.9%
Stockholders' Equity Attributable to Parent 461M USD -22.1%
Liabilities and Equity 586M USD -21.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.9M USD +16.1%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -4.68%
Net Cash Provided by (Used in) Investing Activities 22.1M USD -80.4%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 170M shares +17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.1M USD -167%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.3M USD -49%
Deferred Tax Assets, Valuation Allowance 400M USD +25%
Deferred Tax Assets, Gross 418M USD +21.7%
Operating Lease, Liability 95.8M USD -3.87%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 1.52M USD -70.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -287M USD +19.9%
Lessee, Operating Lease, Liability, to be Paid 129M USD -6.46%
Property, Plant and Equipment, Gross 151M USD +0.22%
Operating Lease, Liability, Current 6.93M USD +12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +4.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.9M USD +3.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32.7M USD -13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.6M USD +6.19%
Deferred Tax Assets, Operating Loss Carryforwards 211M USD +21.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 18.9M USD +29.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.1M USD +6.18%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 0 USD
Depreciation, Depletion and Amortization 14.2M USD -0.7%
Share-based Payment Arrangement, Expense 59.1M USD -26.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%